

EVA Holdings (838 HK)

Poised for higher growth in 2H22

We hosted a conference call with EVA's management for investors on 19 Jul 2022. We see higher growth potential in 2H22, after its positive profit alert of 33-50% YoY growth in 1H22 announced on 18 Jul 2022. We maintain our BUY rating and target price of HK\$ 3.00.

- **Higher ASP for Tesla front seats to offset slight volume miss.** Although Tesla's production volume in North America increases by about 10% MoM according to management, its full-year production volume could still be lower than originally anticipated, capped by battery capacity. However, EVA has secured two more seat related components from Tesla, which could lift its content per vehicle by HK\$ 30 (from HK\$ 190 to HK\$ 220), or HK\$ 20-30mn of revenue contribution in FY22E, offsetting the potential production volume miss.
- **High revenue growth for OA in FY22-23E and better earnings quality in FY23E.** Management expects office automation (OA) revenue to rise 20% YoY in FY22E, contributed by its Weihai and Vietnam plants (about half each). Management also expects OA revenue to rise another 20% YoY in FY23E, mainly from its Weihai plant with more self-made components for the OA assembly business, which could widen the margins.
- **New businesses may start to bear fruit from 2H22.** EVA has been exploring new businesses, especially in those high-growth sectors (such as new-energy vehicle, solar, energy storage and data server), by leveraging its expertise in mould. We expect EVA to secure orders from a few new clients in 2H22 and generate significant revenue from FY23E.
- **Valuation/Key risks.** We are of the view that EVA's 1H22 net profit, based on its positive profit alert (HK\$ 90-102mn), should be dragged by COVID-19 and some non-operating items. We maintain our earnings forecasts for FY22-24E, based on the new information listed above.

We use sum-of-the-parts (SOTP) valuation for EVA, as we value HK\$ 2.34 per share for its auto components business, based on 20x of our FY22E P/E; and HK\$ 0.66 per share for its office automation equipment, based on 8.5x of our FY22E P/E. Key risks to our rating and target price include lower sales or margins, and more severe production disruption than we expect.

Earnings Summary

(YE 31 Dec)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue (HK\$ mn)	4,008	5,109	6,353	8,238	9,777
YoY growth (%)	7.0	27.4	24.4	29.7	18.7
Net income (HK\$ mn)	(15)	155	340	545	787
EPS (HK\$)	(0.01)	0.09	0.19	0.30	0.43
YoY growth (%)	N/A	N/A	119.0	60.4	44.4
P/E (x)	N/A	14.7	6.8	4.2	3.1
P/B (x)	0.9	0.8	0.7	0.6	0.5
Yield (%)	0.0	2.0	4.4	6.9	9.8
ROE (%)	(0.6)	5.7	11.5	16.3	20.2
Net gearing (%)	14.1	17.5	5.9	Net cash	Net cash

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	HK\$ 3.00
(Previous TP	HK\$ 3.00)
Up/Downside	+81.8%
Current Price	HK\$ 1.65

China Auto Sector

SHI Ji, CFA
 (852) 3761 8728
 shiji@cmbi.com.hk



Stock Data

Mkt Cap (HK\$ mn)	2,886
Avg 3 mths t/o (HK\$ mn)	22
52w High/Low (HK\$)	2.58/0.66
Total Issued Shares (mn)	1,749
Source: Bloomberg	

Shareholding Structure


Zhang Hwo Jie's Family	44.3%
Others	55.7%
Source: HKEx	

Share Performance

	Absolute	Relative
1-mth	22.2%	24.6%
3-mth	7.1%	7.2%
6-mth	-7.8%	6.5%

Source: Bloomberg

12-mth Price Performance



Source: Bloomberg

Auditor: PricewaterhouseCoopers

Financial Summary

Income statement

YE 31 Dec (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Revenue	4,008	5,109	6,353	8,238	9,777
Cost of sales	(3,270)	(4,096)	(4,930)	(6,364)	(7,461)
Gross profit	738	1,013	1,423	1,874	2,316
Selling exp.	(237)	(315)	(395)	(501)	(603)
Admin exp.	(463)	(506)	(618)	(737)	(812)
Other income	38	32	40	60	80
Other gains / (losses), net	(8)	(5)	3	(8)	(15)
Impairment loss	(34)	(24)	(32)	(32)	(34)
Operating profit	35	195	421	657	932
Net finance costs	(32)	(15)	(20)	(17)	(6)
Share of profit of JV & asso	(16)	0	(2)	1	1
Pre-tax profit	(13)	180	400	641	926
Tax	(2)	(25)	(60)	(96)	(139)
Minority interests	-	-	-	-	-
Net profit	(15)	155	340	545	787

Cash flow summary

YE 31 Dec (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Profit before taxation	(13)	180	400	641	926
Depreciation/amortization	235	276	321	374	403
Change in working capital	194	(213)	(125)	(44)	(131)
Others	37	17	41	(19)	(77)
Net cash from operating	453	259	637	953	1,121
Capex	(243)	(376)	(200)	(250)	(300)
Others	189	39	(52)	(34)	(20)
Net cash from investing	(54)	(337)	(252)	(284)	(320)
Net borrowings	(11)	6	(489)	(430)	(496)
Dividend paid	(50)	(21)	(67)	(127)	(193)
Others	(23)	(3)	(13)	(20)	(15)
Net cash from financing	(84)	(18)	(569)	(576)	(704)
Net change in cash	315	(96)	(183)	93	98
Cash at beginning of the year	1,071	1,406	1,318	1,135	1,228
FX effect	20	9	-	-	-
Cash at the end of the year	1,406	1,318	1,135	1,228	1,326

Balance sheet

YE 31 Dec (HK\$ mn)	FY20A	FY21A	FY22E	FY23E	FY24E
Current assets	3,271	3,642	3,891	4,571	5,175
Cash & equivalents	1,406	1,318	1,135	1,228	1,326
Account receivables	1,028	1,382	1,654	2,031	2,411
Inventories	541	688	810	976	1,063
Other current assets	295	253	292	335	375
Non-current assets	2,831	2,932	2,866	2,771	2,674
PP&E	2,281	2,418	2,357	2,289	2,226
Right-of-use assets	373	384	376	353	316
Investments in associates	33	35	33	34	35
Other non-current assets	144	95	100	95	97
Total assets	6,101	6,574	6,757	7,342	7,849
Current liabilities	2,774	3,226	3,137	3,133	3,181
Bank borrowings	1,277	1,448	1,034	476	145
Payables	1,159	1,373	1,621	2,092	2,453
Contract liabilities	82	68	83	99	98
Other current liabilities	257	338	400	466	486
Non-current liabilities	718	559	505	634	453
Bank borrowings	625	460	410	560	410
Deferred income	20	21	21	21	21
Other non-current liabilities	73	78	74	53	22
Total liabilities	3,492	3,785	3,642	3,767	3,634
Share capital	172	175	178	181	184
Reserves	2,438	2,614	2,936	3,394	4,030
Minority interests	-	-	-	-	-
Shareholders' equity	2,610	2,788	3,114	3,575	4,214
Total equity and liabilities	6,101	6,574	6,757	7,342	7,849

Key ratios

YE 31 Dec	FY20A	FY21A	FY22E	FY23E	FY24E
Sales mix (%)					
Sales of auto components	22.8	26.7	32.2	37.3	44.0
Sales of OA equipment	77.2	73.3	67.8	62.7	56.0
Growth (%)					
Revenue	7.0	27.4	24.4	29.7	18.7
Gross profit	(3.5)	37.2	40.5	31.7	23.5
Operating profit	(71.1)	461.5	116.5	56.0	41.8
Net profit	N/A	N/A	119.0	60.4	44.4
Profit & loss ratio (%)					
Gross margin	18.4	19.8	22.4	22.8	23.7
Operating margin	0.9	3.8	6.6	8.0	9.5
Net profit margin	(0.4)	3.0	5.3	6.6	8.1
Balance sheet ratio					
Net cash (debt)/total equity (x)	(0.1)	(0.2)	(0.1)	0.1	0.2
Current ratio (x)	1.2	1.1	1.2	1.5	1.6
Receivable turnover days	94	99	95	90	90
Inventory turnover days	60	61	60	56	52
Payable turnover days	129	122	120	120	120
Profitability (%)					
ROE	(0.6)	5.7	11.5	16.3	20.2
ROA	(0.3)	2.4	5.1	7.7	10.4
Per share data (HK\$)					
EPS	(0.01)	0.09	0.19	0.30	0.43
DPS	0.00	0.03	0.06	0.09	0.13

Source: Company data, CMBIGM estimates

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.